Primary lymphoma of the central nervous system: just DLBCL or not?

Blood

Volumn 113, Issue 1, 2009, Pages 7-10

  Manuel, Montesinos Rongen ^a   Siebert, Reiner ^b   Deckert, Martina ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HLA ANTIGEN; PROTEIN P14; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CLINICAL FEATURE; DNA METHYLATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE INACTIVATION; HLA SYSTEM; HUMAN; IMMUNOCOMPETENCE; IMMUNOPHENOTYPING; MEMORY CELL; OBSERVATION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SOMATIC MUTATION; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM TUMOR; GENETICS; IMMUNOLOGY; LARGE CELL LYMPHOMA; PATHOLOGY; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE;

EID: 59449099453     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-149005     Document Type: Article

References (34)

1. Deckert M, Paulus W, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumors Pathology & Genetics of Tumours of the Nervous System. Malignant Lymphomas. Lyon: IRAC;2007:188-192.
2. Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107:190-196.
3. Montesinos-Rongen M, Brunn A, Bentink S, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia. 2008;22:400-405.
4. Montesinos-Rongen M, Küppers R, Schlüter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999;155:2077-2086.
5. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood. 1999;94:1738-1746.
6. Montesinos-Rongen M, Schmitz R, Courts C, et al. Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol. 2005;166:1773-1779.
7. Montesinos-Rongen M, Akasaka T, Zühlke-Jenisch R, et al. Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner. Brain Pathol. 2003;13:534-538.
8. Montesinos-Rongen M, Zühlke-Jenisch R, Gesk S, et al. Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol. 2002;61:926-933.
9. Schwindt H, Akasaka T, Zühlke-Jenisch R, et al. Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol. 2006;65:776-782.
10. Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W. Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol. 1999;155:1445-1451.
11. Weber T, Weber RG, Kaulich K, et al. Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol. 2000;10:73-84.
12. Courts C, Montesinos-Rongen M, Martin-Subero JI, et al. Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol. 2007;66:230-237.
13. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood. 2004;103:1869-1875.
14. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346.
15. Courts C, Montesinos-Rongen M, Brunn A, et al. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol. 2008;67:720-727.
16. Chu LC, Eberhart CG, Grossman SA, Herman JG. Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer. 2006;119: 2487-2491.
17. Cobbers JM, Wolter M, Reifenberger J, et al. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol. 1998;8:263-276.
18. Nakamura M, Sakaki T, Hashimoto H, et al. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res. 2001;61:6335-6339.
19. Ferreri AJ, Dell'Oro S, Capello D, et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol. 2004; 126:657-664.
20. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
21. Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107:3716-3723.
22. Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood. 2008;111:3200-3210.
23. Jellinger KA, Paulus W. Primary central nervous system lymphomas-new pathological developments. J Neurooncol. 1995;24:33-36.
24. Brunn A, Montesinos-Rongen M, Strack A, et al. Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol (Berl) 2007;114:271-276.
25. Jahnke K, Coupland SE, Na IK, et al. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. Blood. 2005;106:384-385.
26. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201: 195-200.
27. Booman M, Douwes J, Glas AM, et al. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res. 2006;12:2698-2705.
28. Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immuneprivileged sites. Blood. 2000;96:3569-3577.
29. Riemersma SA, Oudejans JJ, Vonk MJ, et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol. 2005;206:328-336.
30. Booman M, Douwes J, Legdeur MC, van Baarlen J, Schuuring E, Kluin P. From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective outgrowth in two immune sanctuaries [correction of sanctuariesy]. Haematologica. 2007;92:e69-71.
31. Montesinos-Rongen M, Besleaga R, Heinsohn S, et al. Absence of simian virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients. Virchows Arch. 2004;444: 436-438.
32. Montesinos-Rongen M, Hans VH, Eis-Hübinger AM, et al. Human herpes virus-8 is not associated with primary central nervous system lymphoma in HIV-negative patients. Acta Neuropathol (Berl) 2001;102:489-495.
33. Paulus W, Jellinger K, Hallas C, Ott G, Muller-Hermelink HK. Human herpesvirus-6 and Epstein-Barr virus genome in primary cerebral lymphomas. Neurology. 1993;43:1591-1593.
34. Pels H, Montesinos-Rongen M, Schaller C, et al. Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma. Neurology. 2004;63:167-169.